Molecular Partners

• Initial Public Offering on the Nasdaq Global Select Market of 3,000,000 ADSs, corresponding to 3,000,000 underlying ordinary shares and generating gross proceeds of USD 63.8m
• The offer price was set at USD 21.25 per ADS which corresponds to a price of CHF 19.05 per underlying ordinary share and represents a 9.5% discount vis-a-vis the last closing price of Molecular Partners’ shares on the SIX Stock Exchange prior to pricing on 16 June 2021
• The new shares underlying the ADSs represent 9.3% of Molecular Partners’ entire share capital post offering
• Molecular Partners will use the transaction proceeds to fund and expand their current clinical pipeline as well as for working capital and other general corporate purposes
• Kempen & Co has a long-standing relationship  with Molecular Partners, last acting as Joint Bookrunner in the company’s CHF 80.2m capital increase via an Accelerated Bookbuild Offering in July 2020 and, via Kempen & Co’s Trading Desk, executing various block trades over the years, including a major block in Q3 2019
• In 2021 year to date, Kempen & Co has already executed 15 transactions for European life sciences companies of which 4 US Nasdaq IPOs

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the SEK 301m Capital Increase by Q-linea
• Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
• Joint Bookrunner in the €30 million Capital Increase by GenSight Biologics
• Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
• Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
• Joint Bookrunner in the SEK 1.1 billion capital increase by Oncopeptides
• Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
• Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
• Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
• Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
• Bookrunner in the USD 518 million US Public Offering by CureVac
• Lead Manager in the USD 120 million US Public Offering by Merus 
• Financial Adviser to DCprime in its merger with Immunicum 
• Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
• Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
• Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
• Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
• Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
• Bookrunner in the USD 245 million Nasdaq Initial Public Offering by CureVac
• Co-Manager in the USD 49.0 million US Public Offering by Centogene
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
• Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
• Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
• Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253 million
• Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
• Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
• Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
• Co-Manager in the USD 862 million Global Offering by argenx
• Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides